Drug intelligence / Profile preview

RBS-002

Development stage: Preclinical
Lead developer: RophiBio
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

RBS-002 is a monoclonal antibody biosimilar of dupilumab (Dupixent) being developed by RophiBio, a Korean biologics manufacturer and affiliate of Amicogen. The drug targets the interleukin-4 receptor alpha (IL-4Rα) subunit, which is a shared component of the IL-4 and IL-13 receptor complexes. By binding to IL-4Rα, RBS-002 inhibits the signaling of both IL-4 and IL-13, which are key cytokines driving type 2 (Th2) mediated inflammation. RBS-002 is currently in preclinical development for the treatment of various inflammatory diseases, including atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis.

Other names: dupilumab biosimilar

Targets

IL13RA1 (Interleukin-13 receptor subunit alpha-1)IL4R (Interleukin-4 receptor alpha subunit)

Beyond the preview

Go deeper on RBS-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RBS-002.

Explore the full profile